Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials

BACKGROUND: Inhibitors targeting programmed cell death 1 (PD-1) and programmed death-ligand 1 (PD-L1) have unprecedented effects in cancer treatment. However, the objective response rates (ORRs), progression-free survival (PFS), and overall survival (OS) of PD-1/PD-L1 blockade monotherapy have not b...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Bin, Zhao, Hong, Zhao, Jiaxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366397/
https://www.ncbi.nlm.nih.gov/pubmed/32728392
http://dx.doi.org/10.1177/1758835920937612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366397/
https://www.ncbi.nlm.nih.gov/pubmed/32728392
http://dx.doi.org/10.1177/1758835920937612

Ejemplares similares